EA026251B1 - Способ восстановления и регенерации мышц - Google Patents

Способ восстановления и регенерации мышц Download PDF

Info

Publication number
EA026251B1
EA026251B1 EA201370051A EA201370051A EA026251B1 EA 026251 B1 EA026251 B1 EA 026251B1 EA 201370051 A EA201370051 A EA 201370051A EA 201370051 A EA201370051 A EA 201370051A EA 026251 B1 EA026251 B1 EA 026251B1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonist
muscle
subject
κακγ
cell
Prior art date
Application number
EA201370051A
Other languages
English (en)
Russian (ru)
Other versions
EA201370051A1 (ru
Inventor
Масахиро Ивамото
Мауризио Пасифиси
Original Assignee
Томас Джефферсон Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA026251(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Томас Джефферсон Юниверсити filed Critical Томас Джефферсон Юниверсити
Publication of EA201370051A1 publication Critical patent/EA201370051A1/ru
Publication of EA026251B1 publication Critical patent/EA026251B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201370051A 2010-09-01 2011-08-31 Способ восстановления и регенерации мышц EA026251B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01
US61/378,996 2010-09-01
PCT/US2011/049905 WO2012030919A2 (en) 2010-09-01 2011-08-31 Composition and method for muscle repair and regeneration

Publications (2)

Publication Number Publication Date
EA201370051A1 EA201370051A1 (ru) 2014-03-31
EA026251B1 true EA026251B1 (ru) 2017-03-31

Family

ID=45773490

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370051A EA026251B1 (ru) 2010-09-01 2011-08-31 Способ восстановления и регенерации мышц

Country Status (20)

Country Link
US (6) US9789074B2 (https=)
EP (3) EP3721880B1 (https=)
JP (1) JP5986570B2 (https=)
CN (2) CN103200937B (https=)
AU (1) AU2011296080B2 (https=)
BR (1) BR112013004685B1 (https=)
CA (1) CA2809374C (https=)
CL (1) CL2013000580A1 (https=)
CO (1) CO6680694A2 (https=)
DK (2) DK3721880T3 (https=)
EA (1) EA026251B1 (https=)
ES (3) ES2823234T3 (https=)
HU (2) HUE059024T2 (https=)
IL (1) IL224973B (https=)
MX (2) MX361414B (https=)
NZ (1) NZ607547A (https=)
PL (2) PL3721880T3 (https=)
PT (1) PT2613776T (https=)
WO (1) WO2012030919A2 (https=)
ZA (1) ZA201301536B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9492431B2 (en) 2012-11-08 2016-11-15 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
KR102263013B1 (ko) 2013-01-09 2021-06-10 인터내셔날 스템 셀 코포레이션 피부 재생을 촉진시키는 소분자
ES2694831T3 (es) * 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
WO2015188015A1 (en) 2014-06-04 2015-12-10 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
EP3091084A1 (en) 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
AU2017213796A1 (en) * 2016-02-01 2018-09-20 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
JP7023868B2 (ja) 2016-06-08 2022-02-22 クレメンティア ファーマシューティカルズ，インコーポレイテッド 異所性骨化を治療するための方法
CA3043807A1 (en) 2016-11-16 2018-05-24 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
FR3112684B1 (fr) * 2020-07-24 2022-08-12 Univ Grenoble Alpes Composés pour le traitement de l’hémophilie
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
CN117244064A (zh) * 2022-06-16 2023-12-19 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191008C2 (ru) * 1995-10-11 2002-10-20 Сантр Энтернасьональ Де Решерш Дерматоложик Галдерма (С.И.Р.Д.Галдерма) АНТАГОНИСТ-ЛИГАНД RAR-γ ИЛИ АГОНИСТ-ЛИГАНД RAR-α В КАЧЕСТВЕ ИНГИБИТОРА АПОПТОЗА
US20030113913A1 (en) * 2001-11-16 2003-06-19 Peter Maccallum Cancer Institute Method of enhancing self renewal of stem cells and uses thereof
RU2005102593A (ru) * 2002-07-03 2005-10-10 Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани
US20050271705A1 (en) * 2004-04-30 2005-12-08 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery system and related methods
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
US20090214493A1 (en) * 1997-07-14 2009-08-27 Osiris Therapeutics, Inc. Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
EP2110431A1 (en) * 1997-05-13 2009-10-21 Osiris Therapeutics, Inc. Cartilage regeneration using human mesenchymal stem cells
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU4221399A (en) 1998-05-29 1999-12-13 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
US6331570B1 (en) 1998-09-24 2001-12-18 Bristol-Myers Squibb Company Active enantiomer of RARγ-specific agonist
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
CA2402413A1 (en) 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
DE60120151D1 (de) 2000-04-28 2006-07-06 Childrens Medical Center Isolierung von mesenchymalen stammzellen und deren verwendung
SI1324970T1 (sl) 2000-10-02 2009-02-28 Hoffmann La Roche Retinoidi za zdravljenje emfizema
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
BR0212583A (pt) 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
EP1430023B1 (en) 2001-09-18 2009-04-08 F. Hoffmann-La Roche Ag Substituied urea retinoid agonists ii
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
CN1656065A (zh) * 2002-06-04 2005-08-17 盖尔德马研究及发展公司 作为rar受体抑制剂的配体
JP2005532810A (ja) 2002-07-16 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 組織修復および組織形成のために間葉性幹細胞を移植する方法
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
JP2005206544A (ja) * 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
CA2640484A1 (en) 2006-01-26 2007-08-09 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
BRPI0709886A2 (pt) 2006-03-31 2011-07-26 Hoffmann La Roche processo para a preparaÇço de compostos retinàides
TR201819157T4 (tr) 2006-05-16 2019-01-21 Io Therapeutics Llc Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) * 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
US20120277156A1 (en) 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20140220154A1 (en) 2011-07-01 2014-08-07 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service Method of treating pathologic heterotopic ossification
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
ES2694831T3 (es) 2013-05-22 2018-12-27 Yamaguchi University Inhibidor para trastornos retinocoroideos
JP2017536411A (ja) 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
US20180311356A1 (en) 2015-10-19 2018-11-01 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
WO2017112431A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of Michigan Method of treating heterotopic ossification
JP7023868B2 (ja) 2016-06-08 2022-02-22 クレメンティア ファーマシューティカルズ，インコーポレイテッド 異所性骨化を治療するための方法
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191008C2 (ru) * 1995-10-11 2002-10-20 Сантр Энтернасьональ Де Решерш Дерматоложик Галдерма (С.И.Р.Д.Галдерма) АНТАГОНИСТ-ЛИГАНД RAR-γ ИЛИ АГОНИСТ-ЛИГАНД RAR-α В КАЧЕСТВЕ ИНГИБИТОРА АПОПТОЗА
EP2110431A1 (en) * 1997-05-13 2009-10-21 Osiris Therapeutics, Inc. Cartilage regeneration using human mesenchymal stem cells
US20090214493A1 (en) * 1997-07-14 2009-08-27 Osiris Therapeutics, Inc. Cardiac Muscle Regeneration Using Mesenchymal Stem Cells
US20030113913A1 (en) * 2001-11-16 2003-06-19 Peter Maccallum Cancer Institute Method of enhancing self renewal of stem cells and uses thereof
RU2005102593A (ru) * 2002-07-03 2005-10-10 Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани
US20050271705A1 (en) * 2004-04-30 2005-12-08 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery system and related methods
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALEVY O. & LERMAN O. Retinoic acid induces adult muscle cell differentiation mediated by the retinoic acid receptor-α. J. Cell. Physiol. 1993, vol.154, No.3, pages 566-572. See page 568. *
HALEVY O. et al. Retinoic acid induces adult muscle cell differentiation mediated by the retinoic acid receptor-alpha. J. Cell Physiol., 1993 Mar; 154(3):566-572 [онлайн]. Найдено из PubMed, PMID: 8382210 *
SOPRANO D.R. et al. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitam. Horm. 2007, vol.75, pages 69-95. See line 19 on page 75 - line 36 on page 78 *

Also Published As

Publication number Publication date
CN103200937A (zh) 2013-07-10
PL2613776T3 (pl) 2021-01-11
CN111773213A (zh) 2020-10-16
US9314439B2 (en) 2016-04-19
DK2613776T3 (da) 2020-10-19
EP4066826B1 (en) 2024-03-06
US11433039B2 (en) 2022-09-06
EA201370051A1 (ru) 2014-03-31
WO2012030919A3 (en) 2012-07-05
HUE051664T2 (hu) 2021-03-29
EP2613776A2 (en) 2013-07-17
AU2011296080A1 (en) 2013-03-14
CO6680694A2 (es) 2013-05-31
MX2018015032A (es) 2021-12-08
ES2975123T3 (es) 2024-07-03
DK3721880T3 (da) 2022-05-09
CL2013000580A1 (es) 2013-07-12
PL3721880T3 (pl) 2022-05-23
US9789074B2 (en) 2017-10-17
US20140363402A1 (en) 2014-12-11
BR112013004685A2 (pt) 2019-04-24
AU2011296080B2 (en) 2014-12-04
IL224973B (en) 2018-06-28
CN111773213B (zh) 2023-02-24
US20180000762A1 (en) 2018-01-04
BR112013004685B1 (pt) 2021-09-21
US20230201146A1 (en) 2023-06-29
EP3721880B1 (en) 2022-02-02
NZ607547A (en) 2015-06-26
CN103200937B (zh) 2020-07-03
US10292954B2 (en) 2019-05-21
US20200069620A1 (en) 2020-03-05
WO2012030919A2 (en) 2012-03-08
US12023312B2 (en) 2024-07-02
EP4066826C0 (en) 2024-03-06
MX2013002275A (es) 2013-05-22
JP5986570B2 (ja) 2016-09-06
EP4066826A1 (en) 2022-10-05
EP2613776B1 (en) 2020-07-29
JP2013536855A (ja) 2013-09-26
ES2823234T3 (es) 2021-05-06
CA2809374C (en) 2021-02-23
PT2613776T (pt) 2020-10-21
CA2809374A1 (en) 2012-03-08
ES2912593T3 (es) 2022-05-26
EP3721880A1 (en) 2020-10-14
US20140303223A1 (en) 2014-10-09
ZA201301536B (en) 2015-06-24
US20250108022A1 (en) 2025-04-03
MX361414B (es) 2018-12-05
HUE059024T2 (hu) 2022-10-28
EP2613776A4 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
EA026251B1 (ru) Способ восстановления и регенерации мышц
US20200261510A1 (en) Therapeutics Using Adipose Cells and Cell Secretions
JP2022095884A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
KR20120034167A (ko) 진피세포의 트리코겐 효능을 증가시키기 위한 방법 및 조성물
Ferrie et al. Exogenously delivered iPSCs disrupt the natural repair response of endogenous MPCs after bone injury
HK40080448B (en) Retinoic acid receptor gamma agonists for muscle repair and regeneration
HK40080448A (en) Retinoic acid receptor gamma agonists for muscle repair and regeneration
HK40036876B (en) Composition and method for muscle repair and regeneration
HK40036876A (en) Composition and method for muscle repair and regeneration
HK40039711A (en) Composition and method for muscle repair and regeneration
HK40039711B (en) Composition and method for muscle repair and regeneration
AU2015200760A1 (en) Composition and method for muscle repair and regeneration
HK1186670A (en) Composition and method for muscle repair and regeneration
HK1186670B (zh) 用於肌肉修复和再生的组合物和方法
Satheesh Kumar et al. A review: Development of bovine mammary glandular structure in immuno-deficient mice and expression profiling of morphogenesis related genes